Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Multiple myeloma: US-approved treatments and how Gulf families can access them

Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Multiple myeloma: the short answer

The US FDA has approved eight medicines on this page for multiple myeloma, each for specific patients. Six of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Darzalex, Carvykti, Abecma, Tecvayli, Talvey, Elrexfio, Lynozyfic and Xpovio.
Gulf registration (checked 17 October 2026): see each medicine below.
Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital; cell and gene therapies at a qualified center.
Price: Quote on request.

What is multiple myeloma?

Multiple myeloma is a cancer that starts in plasma cells, a type of white blood cell that is part of the immune system. Over time, myeloma cells collect in the bone marrow and in the solid parts of bones.^[1]

Common symptoms include bone pain, often in the back or ribs, broken bones, weakness or tiredness, weight loss, frequent infections and fevers, strong thirst and frequent urination. It is more common in older people and can run in families.^[1]

Doctors diagnose myeloma with lab tests, imaging and a bone marrow biopsy. People without symptoms may not need treatment right away. Treatment can include chemotherapy, stem cell transplantation, radiation and targeted therapies. Newer US options for relapsed disease include antibody treatments, bispecific antibodies and CAR-T cell therapies.^{[1, 2, 3]}

Multiple myeloma in the Gulf

A private hospital in Abu Dhabi reported 48 adults who had stem cell transplants. Multiple myeloma was the main reason for autologous transplants (using the patient's own cells), and 1-year survival after autologous transplant was 97%.^[4]

In Bahrain, multiple myeloma made up 16.2% of primary bone marrow cancers in Bahraini nationals from 2005 to 2014, with a median age at diagnosis of 57.^[5]

US FDA-approved medicines for multiple myeloma

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

Darzalex (daratumumab)
FDA-approved for adults with multiple myeloma in several combinations, including newly diagnosed patients who cannot have a stem cell transplant (with lenalidomide and dexamethasone) and relapsed or refractory disease. It is given by intravenous infusion.^[2]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[6, 7]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan, India, Pakistan
Carvykti (ciltacabtagene autoleucel)
FDA-approved for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, whose disease is refractory to lenalidomide. It is a CAR-T cell therapy made from the patient's own T cells and given at a certified center.^[3]
Given at a qualified treatment center. Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[6, 7]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan, Turkey, India, Pakistan
Abecma (idecabtagene vicleucel)
FDA-approved for adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. It is a CAR-T cell therapy given at a certified center.^[8]
Given at a qualified treatment center. Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[6, 7]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan, Turkey, India, Pakistan
Tecvayli (teclistamab-cqyv)
FDA-approved for adults with relapsed or refractory multiple myeloma, including in combination with daratumumab after at least one prior line of therapy with a proteasome inhibitor and an immunomodulatory agent. It is a bispecific antibody given by injection under the skin.^[9]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[6, 7]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Iraq, India, Pakistan
Talvey (talquetamab)
FDA-approved for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. It is a bispecific antibody given by injection under the skin.^[10]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[6, 7]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Iraq, India, Pakistan
Elrexfio (elranatamab-bcmm)
FDA-approved for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. It is a bispecific antibody given by injection under the skin.^[11]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[6, 7]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan, Turkey, India
Lynozyfic (linvoseltamab-gcpt)
FDA-approved for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. It is a bispecific antibody given by intravenous infusion.^[12]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[6, 7]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Egypt, India
Xpovio (selinexor)
FDA-approved for adults with multiple myeloma after at least one prior therapy, in combination with bortezomib and dexamethasone, and in later lines with dexamethasone. It is a tablet.^[13]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[6, 7]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman

How families in the Gulf can access these medicines

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[14, 15]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

For Carvykti and Abecma. These treatments are made for each patient or need a specialized procedure, so treatment happens at a qualified center. For most Gulf families that means a referral from the treating specialist to a center that can give the treatment. A local hospital can only give it if the manufacturer agrees to supply that hospital and the regulator approves. We cannot promise that a manufacturer will agree.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for multiple myeloma

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is there an FDA-approved treatment for multiple myeloma?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Darzalex, Carvykti, Abecma, Tecvayli, Talvey, Elrexfio, Lynozyfic and Xpovio. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Darzalex available in Saudi Arabia or the UAE?

Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.

How can a family in the Gulf get Darzalex?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

What does relapsed or refractory mean?

Relapsed means the myeloma came back after treatment. Refractory means it did not respond or stopped responding. Many newer US approvals, such as CAR-T and bispecific antibodies, are for these situations after a set number of earlier treatments listed in each label.

Is stem cell transplantation done in the Gulf?

Yes. For example, a private hospital in Abu Dhabi reported autologous transplants mainly for multiple myeloma. Your hematologist can tell you which centers serve your country.

Sources for the last two answers: ^{[3, 10]} ^[4]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.